Drug Discovery & Development - October 25, 2010
NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, delivered two poster presentations on its compounds at the 48th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Vancouver, Canada.
The presentations included new data from clinical and preclinical studies of NovaBay's Aganocide compounds, which have shown to be highly effective against bacteria, including some multi-drug resistant strains (such as MRSA), viruses and fungi in preclinical testing.
Ron Najafi, Chairman and CEO of NovaBay, said, "These presentations illustrated compelling clinical evidence of effectiveness in the treatment of impetigo and preclinical effectiveness for the treatment of nail fungus infection. The versatility and power of these compounds have been vividly demonstrated as a result."
NovaBay's pipeline of Aganocide compounds is being studied in numerous preclinical and clinical programs. Three clinical programs of the company's lead Aganocide drug candidate are under way for the treatment of impetigo, a highly contagious skin infection; urinary catheter encrustation and blockage; and conjunctivitis, or pink eye.
Date: October 25, 2010
Source: NovaBay Pharmaceuticals, Inc.
The presentations included new data from clinical and preclinical studies of NovaBay's Aganocide compounds, which have shown to be highly effective against bacteria, including some multi-drug resistant strains (such as MRSA), viruses and fungi in preclinical testing.
Ron Najafi, Chairman and CEO of NovaBay, said, "These presentations illustrated compelling clinical evidence of effectiveness in the treatment of impetigo and preclinical effectiveness for the treatment of nail fungus infection. The versatility and power of these compounds have been vividly demonstrated as a result."
NovaBay's pipeline of Aganocide compounds is being studied in numerous preclinical and clinical programs. Three clinical programs of the company's lead Aganocide drug candidate are under way for the treatment of impetigo, a highly contagious skin infection; urinary catheter encrustation and blockage; and conjunctivitis, or pink eye.
Date: October 25, 2010
Source: NovaBay Pharmaceuticals, Inc.
No hay comentarios:
Publicar un comentario